Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity.
OBJECTIVE
It has become clear that von Willebrand factor (vWF) plays important roles in platelet adhesion and aggregation under high blood-flow velocity conditions observed in stenotic atherosclerotic arteries. However, its roles in thrombus formation in vivo on diseased arteries have not been fully understood. We examined the contribution of vWF to thrombus formation and subsequent intimal growth by using a repeated balloon-injury model in rabbits.


RESULTS
Rabbit iliac arteries 4 weeks after a first balloon injury showed 37% luminal stenosis by neointimal growth, and blood velocity increased by 2.1 times compared with that of uninjured arteries. The second balloon injury induced fibrin-rich thrombus formation on the injured neointima. Intravenous administration of a monoclonal antibody against vWF (AJW200, 1.0 mg/kg body weight) remarkably prevented botrocetin-induced platelet aggregation ex vivo for 2 days; moreover, thrombus formation, cell proliferation, and subsequent neointimal growth were significantly reduced at 30 minutes, 5 days, and 4 weeks, respectively, after the second balloon injury.


CONCLUSIONS
These results indicate that vWF plays a potent role in fibrin-rich thrombus formation on the neointima under high blood-flow velocity conditions. Inhibition of plasma vWF activity might be effective for the reduction of thrombus formation and/or subsequent neointimal development after coronary interventions.
Yamashita
Atsushi
A
First Department of Pathology, Miyazaki Medical College, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan.
Asada
Yujiro
Y
Sugimura
Hiroshi
H
Yamamoto
Hiroshi
H
Marutsuka
Kousuke
K
Hatakeyama
Kinta
K
Tamura
Shozo
S
Ikeda
Yasuo
Y
Sumiyoshi
Akinobu
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001783:Blood Flow Velocity; D002404:Catheterization / Q000009:adverse effects; D003251:Constriction, Pathologic; D003435:Crotalid Venoms / Q000494:pharmacology; D018056:Hemorheology; D007083:Iliac Artery / Q000293:injuries / Q000473:pathology*; D008297:Male; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects; D011517:Prothrombin Time; D011817:Rabbits; D012008:Recurrence; D012039:Regional Blood Flow; D013927:Thrombosis / Q000097:blood / Q000209:etiology* / Q000473:pathology; D017539:Tunica Intima / Q000187:drug effects* / Q000293:injuries; D014841:von Willebrand Factor / Q000276:immunology / Q000494:pharmacology* / Q000502:physiology
D000911:Antibodies, Monoclonal; D003435:Crotalid Venoms; D014841:von Willebrand Factor; C030961:botrocetin